<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03087539</url>
  </required_header>
  <id_info>
    <org_study_id>ISU-CLO-201</org_study_id>
    <nct_id>NCT03087539</nct_id>
  </id_info>
  <brief_title>Exploratory P2 Trial to Evaluate Efficacy and Safety of Clotinab® (Abciximab) in Acute MI Patients</brief_title>
  <official_title>Exploratory Phase II Clinical Trial to Evaluate the Efficacy and Safety of Clotinab® (Abciximab) in Acute Myocardial Infarction Patients: Multicenter, Randomized, Double Blind, Placebo-controlled and Parallel Group Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ISU Abxis Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ISU Abxis Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exploratory Phase II Clinical Trial to Evaluate the Efficacy and Safety of Clotinab®
      (Abciximab) in Acute Myocardial Infarction Patients: Multicenter, Randomized, Double-Blind,
      Placebo-controlled and Parallel Group Trial
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was an exploratory phase 2 of Clinical Trial to evaluate the efficacy and safety
      of Clotinab® (Abciximab) in the acute myocardial infarction patients and was designed as a
      multicenter, randomized, double-blinded, placebo-controlled and parallel group study. The
      objective of this phase 2 clinical trial is to evaluate correlation between infarct size and
      major adverse cardiac event (MACE) of acute myocardial infarction patient, prearranged for
      percutaneous coronary intervention(PCI), to measure possibility to use infarct size as a
      primary efficacy test variable in phase 3 for final confirmation of safety and efficacy.

      Also to determine exploratively an average variance estimation of infarct size between study
      drug and placebo to confirm safety and efficacy of study drug, compared to placebo and to use
      the estimation for calculating sample size for phase III clinical trial.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Actual">December 14, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between the Infarct size and MACE</measure>
    <time_frame>18 months</time_frame>
    <description>To determine correlation between infarct size and MACE</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">146</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Clotinab (Abciximab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.25 mg/kg bolus prior to PCI and then 10 ug/kg/min continuous infusion for 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.25 mg/kg bolus prior to PCI and then 10 ug/kg/min continuous infusion for 12 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Abciximab</intervention_name>
    <arm_group_label>Clotinab (Abciximab)</arm_group_label>
    <other_name>Clitinab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Plabebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. Patients with acute myocardial infarction having ST segment, 1 mm or above, from at
             least 2 consecutive segment.

          2. Patients have a plan of Percutaneous Coronary Intervention (PCI)

        Exclusion criteria

          1. History of myocardial infarction

          2. History of hypersensitivity in aspirin, heparin, or protein drugs

          3. Bleeding disorders

          4. Thrombocytopenia (&lt;100,000unit/㎕)

          5. Cardiogenic shock, chronic atrial fibrillation, and cancer

          6. Patients with following criteria: Implanted pacemakers, defibrillators, intracranial
             metallic implants, pregnant, etc

          7. Had a history of surgical operation within 4 weeks

          8. Participated in other clinical trials within 2 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myungho Jeong</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonnam National Univ.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chonnam National University</name>
      <address>
        <city>Gwangju</city>
        <state>Chonnam</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2016</study_first_submitted>
  <study_first_submitted_qc>March 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2017</study_first_posted>
  <last_update_submitted>March 16, 2017</last_update_submitted>
  <last_update_submitted_qc>March 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abciximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoglobulin Fab Fragments</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>No comment</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

